[1] MARION LANIER*. Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure[J]. ACS Medicinal Chemistry Letters, 2017, 8 3: 316-320. DOI:
10.1021/acsmedchemlett.6b00481[2] ROHIT LOOMBA. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial[J]. Hepatology, 2017, 67 2: 549-559. DOI:
10.1002/hep.29514[3] ZOBAIR M. YOUNOSSI. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib[J]. Liver International, 2018, 38 10: 1849-1859. DOI:
10.1111/liv.13706[4] SAMER GAWRIEH MD Naga C M. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis[J]. Clinics in liver disease, 2018, 22 1: Pages 189-199. DOI:
10.1016/j.cld.2017.08.013[5] NING JI . Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells[J]. Cancer letters, 2019, 440: Pages 82-93. DOI:
10.1016/j.canlet.2018.10.007